Aktis Oncology (AKTS) Expected to Announce Earnings on Friday

Key Points

• Q1 2026 earnings are expected to be released on Friday, May 8, with analysts projecting EPS of ($0.33) and revenue of $1.812 million; an earnings call is scheduled for Friday, May 15, 2026 at 4:00 PM ET.
• In the most recent quarter Aktis reported a steep loss of ($18.17) per share on $1.87 million in revenue, highlighting volatile recent results.
• Analyst sentiment is largely positive—six analysts rate the stock a Buy with a consensus price target of $32 (individual targets up to $34).

Aktis Oncology (NASDAQ:AKTS - Get Free Report) is projected to release its Q1 2026 resultson Friday, May 8th. Analysts expect Aktis Oncology to post earnings of ($0.33) per share and revenue of $1.8120 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) last released its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The firm had revenue of $1.87 million for the quarter. On average, analysts expect Aktis Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aktis Oncology Trading Up 0.2%

Aktis Oncology stock opened at $18.75 on Friday. The stock has a 50 day moving average price of $18.80. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $29.16.

Analysts Set New Price Targets

Several research firms have recently weighed in on AKTS. Leerink Partners began coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an "outperform" rating and a $31.00 target price on the stock. TD Cowen started coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set a "buy" rating for the company. Wall Street Zen upgraded shares of Aktis Oncology to a "hold" rating in a report on Saturday, January 17th. JPMorgan Chase & Co. started coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an "overweight" rating and a $30.00 price target for the company. Finally, Bank of America started coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set a "buy" rating and a $34.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $32.00.

About Aktis Oncology

Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.